-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Collegium Pharmaceutical with Overweight Rating, Announces Price Target of $58

Benzinga·12/09/2025 15:36:35
Listen to the news
Barclays analyst Glen Santangelo initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight rating and announces Price Target of $58.